Barclays analyst Balaji Prasad raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $62 from $60 and keeps an Overweight rating on the shares. The firm increased estimates for the company ahead of the Q4 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS: